Under kvartalet har fortsatt fokus varit på utveckling och optimering av plattformen inför stundande...
H&D Wireless ökade sina intäkter med 53 procent i kv2 jämfört med kv1 2021.
Invajo publicerade idag den 31 augusti 2021 sin delårsrapport för årets andra kvartal.
Orphazyme remains committed to pursuing a path to regulatory approval in Europe and the United State...
Redeye anser att nya prekliniska rön ger ett tidigt men lovande stöd för att Cantargias cancerprojek...
Kund- och medarbetsundersökningsbolaget Brilliant Future har haft ett utmanade kvartal.
Nettoomsättningen för Q1'21/22 uppgick till 2 290 mkr (2 100) motsvarande en tillväxt om 9,1 % (13 % organiskt).
Redeye comments on the Q2 report and shortly discusses the two major events during and after the qua...
Tourns nettoomsättning i Q2'21 uppgick till 36,4 mkr (16,2), vilket motsvarar en tillväxt om hela 12...
Redeye's Q1 conclusion is that the US DiviTum approval is on track and that a decision is likely in September alternatively after addressing...
Redeye remains positive to Infracom following a somewhat better Q2 than we expected.
Omställningen i Abelcos investeringsstrategi i slutet av H2-19 har gett effekt och Bolaget har sedan...
Mangold uppdaterar Finepart som utvecklar precisionsbaserad mikrovattenskärningsteknik.
AlzeCure has provided an update on the Phase I trial for ACD856, reporting that some promising data ...
Redeye has a mixed view of Clavister's 2Q21 – net sales were softer than forecast while subscription sales and order intake surprised positi...
Redeye has made some revision to our forecasts and valuation following the Q2 report and other recen...
Redeye views the Q2 report as a non-event since significant revenues should not come now, but later.
Redeye argues that the Q2 report from Zwipe was in line with our expectations and that the company continues to show strong commercial progr...
Redeye comments on aXichem’s Q2’21 report. The report did not include any major surprises, but we be...
Q2 EBIT of SEK 8m 83% below ABGSCe SEK 47m Weaker profitability in Wind Wall Öyfjellet completion st...
Two consecutive quarters with 47% y-o-y sales growth We raise both sales and margin assumptions ‘22e EV/EBIT of 38.
More than 64 million people suffer from heart failure and only 7,000 heart transplants are performed...
Av de cirka 50 miljoner människor som årligen drabbas av sepsis sker behandlingen ofta med antibioti...
The long-term equity story for Vow remains attractive, with significant growth potential within Landbased backed by increased activity withi...
Redeye ser genomförd processutveckling för Uni-Qleaver-teknologin som ett viktigt delsteg för vidare...
We give a brief comment on today's news that Alzecure has recieved approval to start the "MAD"-part ...
